Tacrolimus
- Generic Name
- Tacrolimus
- Brand Names
- Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
- Drug Type
- Small Molecule
- Chemical Formula
- C44H69NO12
- CAS Number
- 104987-11-3
- Unique Ingredient Identifier
- Y5L2157C4J
- Background
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
- Indication
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
- Associated Therapies
- -
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- Conditions
- Interventions
- Biological: Actinium Ac 225-DOTA-DaratumumabProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyBiological: DaratumumabProcedure: EchocardiographyDrug: FludarabineProcedure: Hematopoietic Cell TransplantationBiological: Indium In 111-DOTA-DaratumumabDrug: MelphalanProcedure: Multigated Acquisition ScanProcedure: Radionuclide ImagingProcedure: Single Photon Emission Computed TomographyDrug: SirolimusDrug: TacrolimusRadiation: Total Marrow and Lymphoid Irradiation
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT06287944
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 332
- Registration Number
- NCT06235892
- Locations
- 🇫🇷
CHU de NANTES, Nantes, France
🇳🇴Oslo University Hospital, Oslo, Norway
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
Botox Versus Tacrolimus in Psoriasis Vulgaris
- Conditions
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT06203470
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Dual-Energy Computed TomographyProcedure: EchocardiographyDrug: FludarabineProcedure: Magnetic Resonance ImagingDrug: MelphalanProcedure: Multigated Acquisition ScanBiological: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201Drug: TacrolimusDrug: ThiotepaRadiation: Total Marrow and Lymphoid Irradiation
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT06195891
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Eledon Pharmaceuticals
- Target Recruit Count
- 132
- Registration Number
- NCT06126380
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸Virginia Commonwealth University, Richmond, Virginia, United States
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT06128070
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06084780
- Locations
- 🇺🇸
Cleveland Clinic Digestive Disease & Surgery Institute (DDSI), Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Pharmacokinetics, Effectiveness and Tolerability of Prolonged-release Tacrolimus After Paediatric Kidney Transplantation
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University Hospital, Essen
- Target Recruit Count
- 30
- Registration Number
- NCT06057545
- Locations
- 🇩🇪
University Hospital of Essen, Pediatrics II, Essen, Germany
🇩🇪University Hospital Cologne, Pediatrics, Cologne, Germany
🇩🇪University Hospital of Hamburg-Eppendorf, Hamburg, Germany
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 190
- Registration Number
- NCT06001385
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Colorado Blood Cancer Institute at Presbyterian St. Luke's, Denver, Colorado, United States
🇺🇸City of Hope, Duarte, California, United States
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Eledon Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT05983770
- Locations
- 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.